Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk?

被引:126
作者
Zimetbaum, Peter J. [1 ]
Thosani, Amit
Yu, Hsing-Ting [2 ]
Xiong, Yan [2 ]
Lin, Jay [3 ]
Kothawala, Prajesh [2 ]
Emons, Matthew [2 ]
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA
[2] Cerner LifeSci, Beverly Hills, CA USA
[3] Sanofi Aventis, Bridgewater, NJ USA
关键词
Anticoagulation; Atrial fibrillation; Atrial flutter; Stroke risk; Warfarin; RHYTHM-CONTROL; ORAL ANTICOAGULATION; MANAGEMENT; THERAPY; PREVENTION; GUIDELINES; IMPACT;
D O I
10.1016/j.amjmed.2009.11.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Clinical guidelines for the management of atrial fibrillation and atrial flutter provide recommendations for anticoagulation based on patients' overall risk of stroke. To determine the real-world compliance of physicians with these recommendations, we conducted a retrospective cohort study examining the utilization of warfarin in atrial fibrillation/flutter patients by stroke risk level. METHODS: Patients with a qualifying atrial fibrillation/flutter diagnosis during >= 18 months' continuous enrollment between January 2003 and September 2007, and with >= 6 months' eligibility after the first atrial fibrillation/flutter diagnosis, were identified from the US Market Scan database (Thomson Reuters, New York, NY). Warfarin use within 30 days of the first diagnosis was assessed according to stroke risk, estimated using the Congestive heart failure, Hypertension, Age >75 years, Diabetes, Stroke (CHADS(2)) score. RESULTS: Of 171,393 patients included in the analysis, 20.0% had a CHADS(2) score of 0 (low risk), 61.6% a score of 1-2 (moderate risk), and 18.4% a score of 3-6 (high risk). Warfarin, recommended for high stroke-risk patients, was given to only 42.1% of those with a CHADS(2) score of 3-6. A similar percentage of patients with moderate (43.5%) or low stroke risk (40.1%) received warfarin. Only 29.6% of high-risk, 33.3% of moderate-risk, and 34.1% of low-risk patients who were started on warfarin received. uninterrupted therapy for 6 months following their initial prescription. CONCLUSIONS: These data suggest that guideline recommendations that anticoagulation should be provided in accordance with stroke risk in atrial fibrillation patients are not routinely followed in clinical practice. The causes and clinical implications of under-utilization of anticoagulation in atrial fibrillation patients with high stroke risk warrant further study. (c) 2010 Elsevier Inc. All rights reserved. The American Journal of Medicine (2010) 123, 446-453
引用
收藏
页码:446 / 453
页数:8
相关论文
共 35 条
[1]   Impact of atrial fibrillation on the risk of death [J].
Benjamin, EJ ;
Wolf, PA ;
D'Agostino, RB ;
Silbershatz, H ;
Kannel, WB ;
Levy, D .
CIRCULATION, 1998, 98 (10) :946-952
[2]   Risk of stroke in patients with atrial flutter [J].
Biblo, LA ;
Yuan, Z ;
Quan, KJ ;
Mackall, JA ;
Rimm, AA .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (03) :346-+
[3]   Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation - The Strategies of Treatment of Atrial Fibrillation (STAF) study [J].
Carlsson, J ;
Miketic, S ;
Windeler, J ;
Cuneo, A ;
Haun, S ;
Micus, S ;
Walter, S ;
Tebbe, U .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (10) :1690-1696
[4]   Effects of increased patient cost sharing on socioeconomic disparities in health care [J].
Chernew, Michael ;
Gibson, Teresa B. ;
Yu-Isenberg, Kristina ;
Sokol, Michael C. ;
Rosen, Allison B. ;
Fendrick, A. Mark .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2008, 23 (08) :1131-1136
[5]   Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor? [J].
Chung, NAY ;
Belgore, F ;
Hee, FLLS ;
Conway, DSG ;
Blann, AD ;
Lip, GYH .
STROKE, 2002, 33 (09) :2187-2191
[6]  
CONNOLLY SJ, 2008, EUR SOC CARD 2008 MU
[7]   Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States [J].
Coyne, Karin S. ;
Paramore, Clark ;
Grandy, Susan ;
Mercader, Marco ;
Reynolds, Matthew ;
Zimetbaum, Peter .
VALUE IN HEALTH, 2006, 9 (05) :348-356
[8]   Role of oral anticoagulation in management of atrial fibrillation [J].
Crystal, E ;
Connolly, SJ .
HEART, 2004, 90 (07) :813-817
[9]   Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study [J].
DiMarco, JP ;
Flaker, G ;
Waldo, AL ;
Corley, SD ;
Greene, HL ;
Safford, RE ;
Rosenfeld, LE ;
Mitrani, G ;
Nemeth, M .
AMERICAN HEART JOURNAL, 2005, 149 (04) :650-656
[10]   Atrial fibrillation is associated with severe acute ischemic stroke [J].
Dulli, DA ;
Stanko, H ;
Levine, RL .
NEUROEPIDEMIOLOGY, 2003, 22 (02) :118-123